Headquartered in Charlestown, MA Fiscal year ends December NASDAQ: SLDB solidbio.com
Solid Biosciences Inc. focuses on creating innovative therapies for neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and Friedreich’s ataxia. With a leading product candidate, SGT-003, aimed at Duchenne muscular dystrophy, the company is at the forefront of gene therapy research. It also explores treatments for cardiac conditions like BAG3-mediated dilated cardiomyopathy. Based in Massachusetts, Solid Biosciences is pioneering in dual gene expression technology and has partnerships to advance gene therapy development.
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
Insider buying was somewhat slow in the middle of January, but some purchases by Warren Buffett's Berkshire Hathaway made headlines.
Solid Biosciences Inc. focuses on creating innovative therapies for neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and Friedreich’s ataxia. With a leading product candidate, SGT-003, aimed at Duchenne muscular dystrophy, the company is at the forefront of gene therapy research.
The Wall Street consensus 12-month price target for SLDB is $18.71.
